

Blackstone to Acquire AYUMI Pharmaceutical

03.27.19



Simpson Thacher is representing Blackstone in connection with its acquisition of the entire equity stake in AYUMI Pharmaceutical. The acquisition will mark Blackstone's first control private equity investment in Japan. The transaction is expected to close in the second quarter of 2019 and is subject to regulatory approvals and customary closing conditions.

AYUMI Pharmaceutical is a leading specialty pharmaceutical company in Japan focused on Anti-Rheumatism and Orthopedics.

The Simpson Thacher team for the transaction includes David Sneider, Ian Ho and Yui Hirohashi (M&A); Shahpur Kabraji and Atsushi Usui (Credit); Etienne Renaudeau and Megan Griffith (Antitrust); Steven Klar (Funds); and Jon Goldstein (Tax).

Team and Contacts

Ian Ho

Partner

iho@stblaw.com

+852-2514-7685

Atsushi Usui

Registered Foreign Lawyer

atsushi.usui@stblaw.com

+852-2514-7674

Steven Klar

Partner

steven.klar@stblaw.com

+1-212-455-2988

Shahpur Kabraji

Partner

skabraji@stblaw.com

+44-(0)20-7275-6588

Étienne Renaudeau

Partner

erenadeau@stblaw.com

+44-(0)20-7275-6559

Jonathan Goldstein

Partner

jgoldstein@stblaw.com

+1-212-455-2048

